One biotech company put the mission of this week’s Exponential Medicine Conference to work by proving that is is possible to deliver real-time, accurate DNA testing. Exponential Medicine is a unique four-day conference that gathers world-class faculty, innovators and entrepreneurs from across the biomedical and technology spectrum to “explore the convergence of fast moving technologies.” [Read more…]
Bioquark Inc. and RegenerAge SAPI de CV will focus on translational therapeutic applications of a range of regenerative and rejuvenation based healthcare interventions, with the goal of reducing human degeneration, suffering, and death.
Philadelphia, PA, USA/ Mexico City, Mexico; JULY 19, 2016 – Bioquark, Inc., a life sciences company focused on the development of novel bioproducts for complex regeneration, disease reversion, and aging, and RegenerAge SAPI de CV, a clinical company focused on translational therapeutic applications of a range of regenerative and rejuvenative healthcare interventions, have announced a collaboration to focus on novel combinatorial approaches in human disease and wellness. SGR-Especializada (http://www.sgr-especializada.com/), regulatory experts in the Latin American healthcare market, assisted in the relationship.
“We are very excited about this collaboration with RegenerAge SAPI de CV,” said Ira S. Pastor, CEO, Bioquark Inc. “The natural synergy of our cellular and biologic to applications of regenerative and rejuvenative medicine will make for novel and transformational opportunities in a range of degenerative disorders.” [Read more…]
Below is a press release from Santa Clara Valley Medical Center (SCVMC), a site in the AST-OPC1 SCiSTAR Phase 1/2a clinical trial in complete cervical spinal cord injury, which is being sponsored by BioTime, Inc. (NYSE MKT: BTX) subsidiary Asterias Biotherapeutics (NYSE MKT: AST).
The clinical trial will test the safety of three varying doses of AST-OPC1, which are oligodendrocyte progenitors that have the capacity to differentiate into a variety of brain cells. The California Institute of Regenerative Medicine (CIRM) also released a blog post about the procedure conducted at SCVMC.
The SCiSTAR study being run by Asterias Biotherapeutics is funded in part by a $14.3 million grant from CIRM. [Read more…]
Headquartered in Madison, Wisconsin, Cellular Dynamics International (CDI) is powerhouse within the induced pluripotent stem cell (iPSC) industry. The company was founded in 2004 and listed on NASDAQ stock exchange in July 2013. Today, the company has more than than 150 employees, as well as an extremely robust patent portfolio of more than 800 stem cell related patents of which approximately 130 pertain to iPSCs.
In major news released this week, CDI announced that it has partnered with the National Eye Institute to develop cell transplantation therapies for retinal degenerative disease. [Read more…]
The human cell culture specialists showcase innovative tools and applications for disease modelling and drug discovery
Cambridge, UK, 1 June 2016: Axol Bioscience, a biotechnology company specialising in the supply of human induced pluripotent stem cell (iPSC)-derived cells has expanded its range of drug discovery and disease modelling tools. Axol will launch three exciting products at International Society for Stem Cell Research (ISSCR) 2016 taking place in San Francisco, CA from 22 – 25 June. This includes: Human iPSC-Derived Atrial Cardiomyocytes, Human iPSC-Derived Endothelial Colony Forming Cells (ECFCs) and axolGEMs (Genetically Edited Models), Axol’s new range of isogenic human iPSC-derived cells carrying disease-relevant mutations developed in partnership with Horizon Discovery plc. Axol and its collaborators will also be presenting an Innovation Showcase and posters highlighting the characteristics and functional applications of its human iPSC-derived neural cells and cardiomyocytes. [Read more…]